The real-world characteristics of Pulmonary Hypertension with Lung Disease and/or Hypoxia (PH-LD) and PH with Interstitial Lung Disease (PH-ILD) remain largely unknown. This study?s objective is to characterize the epidemiology, treatment patterns, and burden of PH-LD and PH-ILD, and the treatment patterns of Pulmonary Arterial Hypertension (PAH).

Retrospective longitudinal cohort study using claims data from France (PMSI, SNDS), Germany (SHI Funds), and electronic medical records (EMR) from the UK (CPRD/HES) from Jan-2015 to Dec-2021. Two algorithms to identify patients with PH-LD and PAH were adapted based on input of clinicians actively treating PH patients.

PH-LD/ILD were identified based on the combination of PH-recorded diagnosis with LD/ILD records in the prior 24 months. PAH patients were identified based on a combination of PH diagnosis, visit to a PH center (if available), Right Heart Catheterization (RHC), and PAH-specific drugs. Patient baseline characteristics e.g., sociodemographic data, and comorbidities were described. Resource use, including hospital care (e.g., hospitalizations, length of stay, technical procedures) and primary care use (e.g., office visits, prescriptions) was measured. Real-world outcomes including mortality will be presented. Lastly, the treatment patterns (e.g., new therapies, switches) were also described for the three cohorts.

This pan-European RWE study provides valuable insights into the epidemiology, management, and real-world outcomes of PAH, PH-LD, and PH-ILD. Limitations associated with claims and EMR data sources apply.